Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 109; no. 2; pp. 646 - 651
Main Authors:	Ingelman-Sundberg, Hanna M, Blixt, Lisa, Wullimann, David, Wu, Jinghua, Gao, Yu, Healy, Katie, Muschiol, Sandra, Bogdanovic, Gordana, Åberg, Mikael, Kjellander, Christian, Grifoni, Alba, Sette, Alessandro, Aleman, Soo, Chen, Puran, Blennow, Ola, Hansson, Lotta, Ljunggren, Hans-Gustaf, Chen, Margaret Sällberg, Buggert, Marcus, Österborg, Anders
Format:	Journal Article
Language:	English
Published:	Italy Fondazione Ferrata Storti 2024 Ferrata Storti Foundation
Subjects:	Adaptive Immunity Antibodies, Viral COVID-19 Humans Letter to the Editor Leukemia, Lymphocytic, Chronic, B-Cell Medicin och hälsovetenskap Mucous Membrane SARS-CoV-2
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Correspondence-2 content type line 23 The datasets analyzed during the current study are available from the corresponding author on reasonable request. Disclosures HMIS, LB, AÖ, GB, SA, MSC, HGL, and MB contributed to the conceptualization, funding acquisition, and discussion of data. DW, JW, YG, KH, PC, MÅ, and SM performed experiments and analyzed data. LB, HMIS, CK, LH, and AÖ recruited study participants, conducted the management of participants during the study, and analyzed data. AG and AS provided peptide pools to measure the Spike-specific T-cell responses. OB provided information on sequencing. HMIS, LB, DW, KH, MSC, AÖ, HGL, and MB wrote the original draft of the manuscript. All authors reviewed and edited revisions of the manuscript and had final responsibility for the decision to submit for publication. Contributions MB is a consultant and has received honoraria from MSD, Pfizer, Mabtech, BMS, and Oxford Immunotec. AS is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim. La Jolla Institute for Immunology has filed for patent protection for various aspects of T-cell epitope and vaccine design work. All other authors have no conflicts of interest to disclose. Data-sharing statement
ISSN:	0390-6078 1592-8721 1592-8721
DOI:	10.3324/haematol.2023.282894